2022
Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
Tuan J, Kayani J, Fisher A, Kotansky B, Dembry L, Datta R. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e83. PMID: 36483361, PMCID: PMC9726471, DOI: 10.1017/ash.2022.229.Peer-Reviewed Original ResearchDalbavancin administrationOutpatient parenteral antimicrobial therapyDose of dalbavancinMedian antibiotic durationSoft tissue infectionsParenteral antimicrobial therapyAntibiotic durationDeveloped hepatotoxicityClinical cureSeptic arthritisClinical outcomesAntimicrobial therapyPatientsAdministrationDaysEndocarditisArthritisBacteremiaOsteomyelitisHepatotoxicityTherapyDalbavancinInfectionDose
2020
Adverse Events and Healthcare Utilization Associated With Outpatient Parenteral Antimicrobial Therapy Among Older Versus Younger Adults
Brzozowski K, Datta R, Canterino J, Malinis M, Juthani-Mehta M. Adverse Events and Healthcare Utilization Associated With Outpatient Parenteral Antimicrobial Therapy Among Older Versus Younger Adults. Open Forum Infectious Diseases 2020, 7: ofaa358. PMID: 33094112, PMCID: PMC7566523, DOI: 10.1093/ofid/ofaa358.Peer-Reviewed Original Research
2019
Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures
Datta R, Wang T, Zhu M, Dembry LM, Han L, Allore H, Quagliarello V, Juthani-Mehta M. Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures. Infection Control And Hospital Epidemiology 2019, 40: 470-472. PMID: 30821230, PMCID: PMC6482377, DOI: 10.1017/ice.2019.22.Peer-Reviewed Original ResearchConceptsUrinary tract infectionIncidence rate ratiosAdvanced cancer patientsAsymptomatic bacteriuriaCancer patientsAntimicrobial therapySymptomatic urinary tract infectionPotential urinary tract infectionTract infectionsInappropriate therapyAntimicrobial daysComfort measuresBacteriuriaCandiduriaCFU/mLPatientsTherapyRate ratioMLInfection
2018
Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report
Datta R, Advani S, Rink A, Bianco L, Van Ness PH, Quagliarello V, Juthani-Mehta M. Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report. Open Access Journal Of Gerontology & Geriatric Medicine 2018, 4: 555636. PMID: 30465048, PMCID: PMC6241532, DOI: 10.19080/oajggm.2018.04.555636.Peer-Reviewed Original ResearchLong-term care residentsUrinary tract infectionUrine isolatesCare residentsTract infectionsUncomplicated urinary tract infectionsLong-term care facilitiesTrimethoprim/sulfamethoxazoleEmpiric therapyCommon indicationOptimal therapyUrine cultureUrinary isolatesAntimicrobial therapyClinical trialsNitrofurantoin susceptibilityCare facilitiesFluoroquinolone susceptibilityAntimicrobial susceptibilityPredominant organismTherapyInfectionCefazolinIsolatesBacterial isolates
2017
Burden and Management of Multidrug-Resistant Organisms in Palliative Care
Datta R, Juthani-Mehta M. Burden and Management of Multidrug-Resistant Organisms in Palliative Care. Palliative Care And Social Practice 2017, 10: 1178224217749233. PMID: 29317826, PMCID: PMC5753884, DOI: 10.1177/1178224217749233.Peer-Reviewed Original ResearchMultidrug-resistant organismsPalliative careTerminal illnessGoals of palliationPalliative care patientsPalliative care settingAvailable treatment optionsInfection prevention measuresQuality of lifeCommon complicationContact precautionsMetastatic diseaseCare patientsPatient isolationTreatment optionsSymptom assessmentCare discussionsAntimicrobial therapyCommon signsCare settingsCognitive impairmentPsychological burdenPatientsInfectionAdverse effects